Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interaction between prostaglandin E1 and nitric oxide (NO).

R Katzenschlager1, K Weiss, W Rogatti

  • 1Wilhelm Auerswald Atherosclerosis Research Group (ASF) Vienna, Austria.

Thrombosis Research
|May 15, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Isradipine increases vascular prostaglandin I2-formation while the thromboxane B2-synthesis is diminished.

Thrombosis research·1995
Same author

Passive smoking and cardiovascular risk.

Archives of internal medicine·1995
Same author

Gamma irradiation is not a novel approach to inhibit neointimal hyperplasia after arterial injury.

Stroke·1995
Same author

Arterial wall rather than platelets is responsible for diminished thrombogenicity during isradipine therapy.

Journal of cardiovascular pharmacology·1995
Same author

Evidence for lipid regression in humans in vivo performed by 123iodine-low-density lipoprotein scintiscanning.

Annals of the New York Academy of Sciences·1995
Same author

[1995 consensus guidelines for cholesterol. Society of Physicians in Vienna].

Wiener klinische Wochenschrift·1995
Same journal

Apoptotic versus procoagulant platelets: similar "necrotic" phenotype and procoagulant activity in vitro, but distinct adhesive protein composition.

Thrombosis research·2026
Same journal

Heatstroke-induced coagulopathy: A scoping review of therapeutic strategies and outcome reporting.

Thrombosis research·2026
Same journal

Mapping thrombus habitat: Non-contrast MRI radiomics and pixel-tile histomics approach to track venous thrombosis evolution in mice.

Thrombosis research·2026
Same journal

A study protocol for a randomised controlled trial evaluating the safety and efficiency of the YEARS algorithm versus computed tomography pulmonary angiography only for suspected acute pulmonary embolism in patients with cancer: the Hydra Study.

Thrombosis research·2026
Same journal

Associating the phenotypic expression of platelets with disease type through image-based single-cell profiling.

Thrombosis research·2026
Same journal

The mechanisms of contractile dysfunction following chronic limited platelet activation in (pro)thrombotic conditions.

Thrombosis research·2026
See all related articles

Prostaglandin E1 (PGE1) and nitric oxide (NO) together enhance antiplatelet effects, similar to prostaglandin I2 (PGI2). This combination shows synergistic action, offering potential for clinical antiplatelet therapy.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Hematology

Background:

  • Prostaglandin I2 (PGI2) and nitric oxide (NO) exhibit synergistic antiplatelet effects.
  • Limited data exist regarding the interaction between Prostaglandin E1 (PGE1) and NO on platelet function.

Purpose of the Study:

  • To investigate the potential synergistic antiplatelet effect between PGE1 and NO in human platelets in vitro.
  • To compare the interaction of PGE1-NO with the known PGI2-NO synergism.

Main Methods:

  • Healthy volunteers' platelet-rich plasma (PRP) was used for in vitro experiments.
  • Platelet aggregation was induced by adenosine diphosphate (ADP).
  • The inhibitory effects of PGE1, NO, and their combination on ADP-induced aggregation were measured.

Related Experiment Videos

Main Results:

  • PGE1 alone inhibited platelet aggregation by 27.8% ± 14.6%.
  • NO alone inhibited platelet aggregation by 26.7% ± 25.5%.
  • The combination of PGE1 and NO resulted in an additive inhibitory effect of 40.6% ± 23.5% on platelet aggregation.

Conclusions:

  • PGE1, similar to PGI2, demonstrates a synergistic antiplatelet action with NO.
  • The combined administration of PGE1 and NO presents a promising strategy for clinical antiplatelet therapy.